The
COVID-19 disease is caused by a positive-stranded RNA virus called SARS-CoV-2.
The virus mainly targets the pulmonary epithelial cells as it’s the initial site of
infection by letting its surface spike protein interact and bind to the host
ACE2 receptor. The internalization and gradual replication of the virus results
in an exaggerated immune response triggering the release of many pro-inflammatory
cytokines and chemokines. This immune storm is responsible for multiple health
hazards in the host ultimately leading to multiple organ failure. Mesenchymal
stem cell therapy offers a promising approach towards mitigating the delirious
effects of the infection in COVID-19 patients. This therapy has shown to
reduce the expression of pro-inflammatory cytokines as well as repair of
damaged tissues in COVID-19 patients. This review has been organized to put
forward the positive aruments and implications in support of mesenchymal stem
cell therapy as a necessary approach for treating COVID-19 patients.